A new, advanced genetic test developed by researchers at the Cyprus Institute of Neurology and Genetics (CING) is transforming preimplantation genetic testing (PGT-M), offering new hope to couples at risk of passing on inherited diseases, according to a CING press release.
According to the Institute, the method is already being used in real cases, helping couples to have children free from conditions such as beta-thalassemia, sickle cell anemia, cystic fibrosis and neurofibromatosis. Around 50,000 babies are born with beta-thalassemia worldwide each year.
PGT-M is used alongside IVF to screen embryos before implantation, ensuring only healthy embryos are selected. The new technique makes testing possible even in complex cases, including new (de novo) mutations or when no family samples are available.
The breakthrough is based on long-read sequencing technology, which allows scientists to analyse larger sections of DNA more quickly and accurately than before. In trials involving 12 high-risk families, the method showed 100% agreement with expected genetic results.
The new approach also reduces preparation time significantly—from several months to less than half—while requiring samples only from the parents.
As the only provider of PGT-M in Cyprus, the Institute now offers this technology to both local and international couples, expanding options for safer family planning, the announcement says.
